Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
PRA Health Sciences, Inc., a leading name in the research and development services sector, is headquartered in the United States. Founded in 1976, the company has established itself as a key player in clinical research, offering a comprehensive range of services that span from Phase I to Phase IV clinical trials. With a strong presence in North America, Europe, and Asia, PRA Health Sciences is renowned for its innovative approach to drug development and patient engagement.
The company’s core offerings include clinical trial management, data analytics, and regulatory consulting, all designed to streamline the drug development process. PRA Health Sciences is distinguished by its commitment to quality and efficiency, which has earned it a prominent position in the global market. Notable achievements include numerous successful partnerships with pharmaceutical and biotechnology firms, solidifying its reputation as a trusted partner in advancing healthcare solutions.
+22 vs industry average
PRA Health Sciences, Inc.’s score of 55 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
PRA Health Sciences, Inc. reported total carbon emissions of approximately 31,296,000 kg CO2e in 2019. This total includes 485,000 kg CO2e from Scope 1 emissions, which primarily stems from stationary combustion, 8,456,000 kg CO2e from Scope 2 emissions, attributed to purchased electricity, and 22,355,000 kg CO2e from Scope 3 emissions, largely from business travel.
Looking back, the company's total carbon emissions were approximately 29,912,000 kg CO2e in 2018, 29,641,000 kg CO2e in 2017, 32,428,000 kg CO2e in 2016, and 25,743,000 kg CO2e in 2015. For 2014, only Scope 1 and Scope 2 emissions were reported, totalling 778,650 kg CO2e and 4,234,160 kg CO2e respectively. Missing data points for Scope 3 emissions in 2014, including purchased goods and services, and employee commute, suggest that a comprehensive total for that year is unavailable.
PRA Health Sciences, Inc. has set near-term net-zero targets. The company aims to reduce its Scope 1 emissions to near zero by the middle of this decade (2023-2025). Similarly, it plans to reduce its Scope 2 emissions to near zero within the same timeframe. These commitments are detailed in their 2019 responsibility report.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more